TOKYO -- Nearly 400,000 people come down with dengue fever every year. The mosquito-borne tropical disease appears especially fond of Asia, which accounts for 70% of the infections. While France's Sanofi licensed the first dengue vaccine in 2015, the counteractant has been ineffective for young children.
Rajeev Venkayya, president of Takeda Pharmaceutical's global vaccine business, expects a new neutralizer to fill the gap in Asia.
